Molecular Physiology Unit, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México.
Nephrol Dial Transplant. 2010 Jul;25(7):2150-8. doi: 10.1093/ndt/gfq020. Epub 2010 Feb 5.
Polymerized type I collagen (P-collagen) has been successfully used to reduce human hypertrophic scars due to its anti-fibrotic and anti-inflammatory properties. We therefore carried out a study to determine if P-collagen reduces functional and structural injury in chronic cyclosporine [cyclosporine A (CsA)] nephropathy.
Four groups of six male Wistar rats fed with a low sodium diet were treated with vehicle, P-collagen (0.8 mg/day, i.p.), CsA (15 mg/kg) or CsA + P-collagen for 15 days. Mean arterial pressure, renal blood flow and glomerular filtration rate were measured in all groups. Structural injury such as arteriolopathy, tubulo-interstitial fibrosis (TI-fibrosis) and positive apoptotic cells were quantified. The mRNA expression levels of transforming growth factor-beta (TGF-beta), kidney injury molecule (Kim-1), alpha-smooth muscle actin (alpha-SMA), glutathione peroxidase, catalase and Cu/Zn superoxide dismutase (SOD) as well as MnSOD were assessed. Antioxidant enzyme activity, renal lipoperoxidation and urinary excretion of oxygen peroxide (UH(2)O(2)V) were determined.
Cyclosporine produced renal dysfunction and induced the development of arteriolopathy, TI-fibrosis and tubular apoptosis. These alterations were associated with increases in TGF-beta, Kim-1 and alpha-SMA mRNA levels as well as with a significant increase of oxidative stress and a reduction of SOD activity. P-Collagen partially ameliorated CsA-induced renal dysfunction and structural injury and prevented both tubular apoptosis and increased oxidative stress. This renoprotective effect was found to be associated with a reduction of TGF-beta, Kim-1 and alpha-SMA mRNA levels.
This study has therefore demonstrated that P-collagen appears to have anti-fibrotic and anti-apoptotic properties and highlights the possibility that the compound might be useful in a strategy to reduce chronic CsA nephrotoxicity.
聚合型 I 型胶原蛋白(P-胶原蛋白)因其抗纤维化和抗炎特性已成功用于减少人类增生性瘢痕。因此,我们进行了一项研究,以确定 P-胶原蛋白是否能减轻慢性环孢素[环孢素 A(CsA)]肾病的功能和结构损伤。
四组 6 只雄性 Wistar 大鼠喂食低钠饮食,分别给予载体、P-胶原蛋白(0.8mg/天,腹腔注射)、CsA(15mg/kg)或 CsA+P-胶原蛋白治疗 15 天。所有组均测量平均动脉压、肾血流量和肾小球滤过率。定量评估结构损伤,如小动脉病、肾小管间质纤维化(TI 纤维化)和阳性凋亡细胞。评估转化生长因子-β(TGF-β)、肾损伤分子(Kim-1)、α-平滑肌肌动蛋白(α-SMA)、谷胱甘肽过氧化物酶、过氧化氢酶和铜/锌超氧化物歧化酶(SOD)以及 MnSOD 的 mRNA 表达水平。测定抗氧化酶活性、肾脂质过氧化和尿过氧化物(UH(2)O(2)V)排泄。
环孢素导致肾功能障碍,并诱导小动脉病、TI 纤维化和肾小管凋亡的发展。这些改变与 TGF-β、Kim-1 和α-SMA mRNA 水平的增加以及氧化应激的显著增加和 SOD 活性的降低有关。P-胶原蛋白部分改善了 CsA 诱导的肾功能障碍和结构损伤,并预防了肾小管凋亡和氧化应激的增加。这种肾保护作用与 TGF-β、Kim-1 和α-SMA mRNA 水平的降低有关。
因此,本研究表明 P-胶原蛋白具有抗纤维化和抗凋亡特性,并强调了该化合物可能在减少慢性 CsA 肾毒性的策略中有用。